Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAPYRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAPYRIDINE.
SULFACETAMIDE SODIUM vs SULFAPYRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic